LOXL2 and prostate cancer: On the other hand, Lysyl oxidase-like 2 (LOXL2), a protein that induces EMT, is involved in radiotherapy resistance in prostate cancer cells and in xenografts mice model (Cano et al. 2012; Martin et al. 2016).